Functionalized polysaccharides emerge as a strategy to combat biofilm-driven gynecological infections and enhance tissue repair
Background
<b>Gynecological infections</b> like <b>bacterial vaginosis (BV)</b> and <b>pelvic inflammatory disease (PID)</b>, alongside implant-related complications, pose significant health challenges. Biofilm-forming pathogens such as Gardnerella vaginalis and Staphylococcus aureus drive chronic infections, resisting antibiotics and host immunity. Current treatments struggle with <b>antibiotic resistance</b> and high recurrence rates, while gynecological implants (e.g., IUDs) face infection rates up to <b>20%</b>, leading to device failure. A critical gap exists for innovative biomaterials that prevent microbial colonization and support tissue repair.
Why It Matters
<b>Developing functionalized polysaccharides offers a transformative approach to women's health</b>, addressing the dual challenge of persistent gynecological infections and the need for regenerative therapies. By preventing <b>biofilm formation</b> and promoting tissue repair, these novel biomaterials could significantly reduce infection recurrence, improve the longevity and safety of gynecological implants, and mitigate the impact of rising <b>antibiotic resistance</b>. This could lead to more effective, non-antibiotic treatment strategies, enhancing patient quality of life and potentially reducing the need for surgical interventions related to implant failure.
polysaccharides
gynecological-infections
biofilm
antibiotic-resistance
tissue-regeneration
biomaterials